181 related articles for article (PubMed ID: 19439429)
41. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
42. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.
Holmqvist ME; Wedrén S; Jacobsson LT; Klareskog L; Nyberg F; Rantapää-Dahlqvist S; Alfredsson L; Askling J
Arthritis Rheum; 2009 Oct; 60(10):2861-9. PubMed ID: 19790058
[TBL] [Abstract][Full Text] [Related]
43. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.
Wolfe F; Michaud K; Chakravarty EF
Rheumatology (Oxford); 2006 Nov; 45(11):1370-5. PubMed ID: 17003175
[TBL] [Abstract][Full Text] [Related]
44. Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate.
Sibilia J; Lioté F; Mariette X
Rev Rhum Engl Ed; 1998 Apr; 65(4):267-73. PubMed ID: 9599795
[TBL] [Abstract][Full Text] [Related]
45. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.
van den Borne BE; Landewé RB; Houkes I; Schild F; van der Heyden PC; Hazes JM; Vandenbroucke JP; Zwinderman AH; Goei The HS; Breedveld FC; Bernelot Moens HJ; Kluin PM; Dijkmans BA
Arthritis Rheum; 1998 Nov; 41(11):1930-7. PubMed ID: 9811046
[TBL] [Abstract][Full Text] [Related]
46. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis.
Radovits BJ; Popa-Diaconu DA; Popa C; Eijsbouts A; Laan RF; van Riel PL; Fransen J
Ann Rheum Dis; 2009 Aug; 68(8):1271-6. PubMed ID: 18701555
[TBL] [Abstract][Full Text] [Related]
47. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis.
Nyhäll-Wåhlin BM; Petersson IF; Nilsson JA; Jacobsson LT; Turesson C;
Rheumatology (Oxford); 2009 Apr; 48(4):416-20. PubMed ID: 19213849
[TBL] [Abstract][Full Text] [Related]
48. Antirheumatic drugs and the risk of tuberculosis.
Brassard P; Kezouh A; Suissa S
Clin Infect Dis; 2006 Sep; 43(6):717-22. PubMed ID: 16912945
[TBL] [Abstract][Full Text] [Related]
49. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
51. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides.
Pedersen M; Jacobsen S; Klarlund M; Pedersen BV; Wiik A; Wohlfahrt J; Frisch M
Arthritis Res Ther; 2006; 8(4):R133. PubMed ID: 16872514
[TBL] [Abstract][Full Text] [Related]
52. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.
Panoulas VF; Douglas KM; Milionis HJ; Stavropoulos-Kalinglou A; Nightingale P; Kita MD; Tselios AL; Metsios GS; Elisaf MS; Kitas GD
Rheumatology (Oxford); 2007 Sep; 46(9):1477-82. PubMed ID: 17704521
[TBL] [Abstract][Full Text] [Related]
54. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
Davis JM; Maradit Kremers H; Crowson CS; Nicola PJ; Ballman KV; Therneau TM; Roger VL; Gabriel SE
Arthritis Rheum; 2007 Mar; 56(3):820-30. PubMed ID: 17330254
[TBL] [Abstract][Full Text] [Related]
55. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.
Brassard P; Lowe AM; Bernatsky S; Kezouh A; Suissa S
Arthritis Rheum; 2009 Mar; 61(3):300-4. PubMed ID: 19248128
[TBL] [Abstract][Full Text] [Related]
56. Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis.
Mikuls TR; Endo JO; Puumala SE; Aoun PA; Black NA; O'Dell JR; Stoner JA; Boilesen EC; Bast MA; Bergman DA; Ristow KM; Ooi M; Armitage JO; Habermann TM
J Clin Oncol; 2006 Apr; 24(10):1597-602. PubMed ID: 16520462
[TBL] [Abstract][Full Text] [Related]
57. The role of risk factors for periodontal disease in patients with rheumatoid arthritis.
Gleissner C; Willershausen B; Kaesser U; Bolten WW
Eur J Med Res; 1998 Aug; 3(8):387-92. PubMed ID: 9707521
[TBL] [Abstract][Full Text] [Related]
58. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Wolfe F; Caplan L; Michaud K
Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
[TBL] [Abstract][Full Text] [Related]
59. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
60. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.
Augustsson J; Eksborg S; Ernestam S; Gullström E; van Vollenhoven R
Ann Rheum Dis; 2007 Nov; 66(11):1462-6. PubMed ID: 17502359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
